These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35398530)

  • 1. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer.
    Modi S; Giri B; Gupta VK; Lavania S; Sethi V; Sharma NS; Pandey S; Vickers S; Dudeja V; Saluja AK
    Cancer Lett; 2022 Jul; 537():215591. PubMed ID: 35398530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
    Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
    J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
    Rivard C; Geller M; Schnettler E; Saluja M; Vogel RI; Saluja A; Ramakrishnan S
    Gynecol Oncol; 2014 Nov; 135(2):318-24. PubMed ID: 25172764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
    Arora N; Alsaied O; Dauer P; Majumder K; Modi S; Giri B; Dudeja V; Banerjee S; Von Hoff D; Saluja A
    PLoS One; 2017; 12(2):e0171827. PubMed ID: 28192510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.
    Banerjee S; Modi S; McGinn O; Zhao X; Dudeja V; Ramakrishnan S; Saluja AK
    Clin Cancer Res; 2016 Jan; 22(2):415-25. PubMed ID: 26405195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial.
    Lim SH; Saluja A; Vickers S; Hong JY; Kim ST; Lavania S; Pandey S; Gupta VK; Velagapudi MR; Lee J
    Cancer Lett; 2024 Aug; 597():217041. PubMed ID: 38866072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.
    Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK
    Sci Transl Med; 2012 Oct; 4(156):156ra139. PubMed ID: 23076356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
    Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
    Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F.
    Oliveira A; Beyer G; Chugh R; Skube SJ; Majumder K; Banerjee S; Sangwan V; Li L; Dawra R; Subramanian S; Saluja A; Dudeja V
    Lab Invest; 2015 Jun; 95(6):648-659. PubMed ID: 25893635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
    Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity.
    Borazanci E; Saluja A; Gockerman J; Velagapudi M; Korn R; Von Hoff D; Greeno E
    Oncologist; 2024 Feb; 29(2):132-141. PubMed ID: 38169017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
    Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
    Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
    Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
    Sarantis P; Bokas A; Papadimitropoulou A; Koustas E; Theocharis S; Papakotoulas P; Schizas D; Papalampros A; Felekouras E; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minnelide exhibits antileukemic activity by targeting the Ars2/miR-190a-3p axis.
    Yuan L; Jiang X; Jia G; Li Z; Wang M; Hu S; Yang J; Liang F; Zhang F; Gao L; Gao N
    Phytomedicine; 2024 Jul; 130():155724. PubMed ID: 38759317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
    Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
    J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
    Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
    FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.